A novel hydrogen sulfide-releasing donor, HA-ADT, suppresses the growth of human breast cancer cells through inhibiting the PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways
- 1 July 2019
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 455, 60-72
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81802718, U1504817, 81670088)
- Foundation of Science & Technology Department of Henan Province (182102310335, 162102410009, 172102410019)
- Science Foundation of Kaifeng City (1608004, 1703016)
- Science Foundation of Henan University (yqpy20170044)
This publication has 55 references indexed in Scilit:
- Development of PI3K inhibitors: lessons learned from early clinical trialsNature Reviews Clinical Oncology, 2013
- A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cellsNature Communications, 2013
- Alternative dosing of dual PI3K and MEK inhibition in cancer therapyBMC Cancer, 2012
- H2S signalling through protein sulfhydration and beyondNature Reviews Molecular Cell Biology, 2012
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced CancerClinical Cancer Research, 2012
- Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That BlossomedPhysiological Reviews, 2012
- Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leafCancer Letters, 2011
- Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladderHistopathology, 2011
- Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosisBreast Cancer Research, 2011
- Anti-tumor effects of a novel chimeric peptide on S180 and H22 xenografts bearing nude micePeptides, 2010